

Clinpharm Consulting Ltd

Annual Report and Unaudited Financial Statements
for the Year Ended 30 June 2018

Leslie Dark & Co
Chartered Accountants
St Matthew's House
Quays Office Park
Conference Avenue
Portishead
Bristol
BS20 7LZ

Clinpharm Consulting Ltd

Contents

Company Information	<u>1</u>
Accountants' Report	<u>2</u>
Balance Sheet	<u>3</u>
Notes to the Financial Statements	<u>4 to 8</u>

Clinpharm Consulting Ltd

Company Information

Director Mr Sheldon Del Greenwood

Registered office St Matthew's House
Quays Office Park
Conference Avenue
Portishead
Bristol
BS20 7LZ

Accountants Leslie Dark & Co
Chartered Accountants
St Matthew's House
Quays Office Park
Conference Avenue
Portishead
Bristol
BS20 7LZ

**Chartered Accountants' Report to the Director on the Preparation of the Unaudited
Statutory Accounts of
Clinpharm Consulting Ltd
for the Year Ended 30 June 2018**

In order to assist you to fulfil your duties under the Companies Act 2006, we have prepared for your approval the accounts of Clinpharm Consulting Ltd for the year ended 30 June 2018 as set out on pages 3 to 8 from the company's accounting records and from information and explanations you have given us.

As a practising member firm of the Institute of Chartered Accountants in England and Wales (ICAEW), we are subject to its ethical and other professional requirements which are detailed at <http://www.icaew.com/en/members/regulations-standards-and-guidance/>.

This report is made solely to the Board of Directors of Clinpharm Consulting Ltd, as a body, in accordance with the terms of our engagement letter dated 7 July 2014. Our work has been undertaken solely to prepare for your approval the accounts of Clinpharm Consulting Ltd and state those matters that we have agreed to state to the Board of Directors of Clinpharm Consulting Ltd, as a body, in this report in accordance with ICAEW Technical Release 07/16 AAF. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than Clinpharm Consulting Ltd and its Board of Directors as a body for our work or for this report.

It is your duty to ensure that Clinpharm Consulting Ltd has kept adequate accounting records and to prepare statutory accounts that give a true and fair view of the assets, liabilities, financial position and profit of Clinpharm Consulting Ltd. You consider that Clinpharm Consulting Ltd is exempt from the statutory audit requirement for the year.

We have not been instructed to carry out an audit or a review of the accounts of Clinpharm Consulting Ltd. For this reason, we have not verified the accuracy or completeness of the accounting records or information and explanations you have given to us and we do not, therefore, express any opinion on the statutory accounts.

.....
Leslie Dark & Co
Chartered Accountants
St Matthew's House
Quays Office Park
Conference Avenue
Portishead
Bristol
BS20 7LZ

29 March 2019

Clinpharm Consulting Ltd

(Registration number: 08526231)
Balance Sheet as at 30 June 2018

	Note	2018 £	2017 £
Fixed assets			
Tangible assets	<u>4</u>	1,108	646
Current assets			
Debtors	<u>5</u>	-	25,558
Cash at bank and in hand		39,952	10,546
		39,952	36,104
Creditors: Amounts falling due within one year	<u>6</u>	(27,568)	(21,154)
Net current assets		12,384	14,950
Total assets less current liabilities		13,492	15,596
Provisions for liabilities		(211)	(123)
Net assets		13,281	15,473
Capital and reserves			
Called up share capital	<u>7</u>	100	100
Profit and loss account		13,181	15,373
Total equity		13,281	15,473

For the financial year ending 30 June 2018 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies.

Director's responsibilities:

- The members have not required the company to obtain an audit of its accounts for the year in question in accordance with section 476; and
- The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

These financial statements have been prepared in accordance with the special provisions relating to companies subject to the small companies regime within Part 15 of the Companies Act 2006.

These financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime and the option not to file the Profit and Loss Account has been taken.

Approved and authorised by the director on 29 March 2019

.....

Mr Sheldon Del Greenwood
Director

The notes on pages 4 to 8 form an integral part of these financial statements.

Clinpharm Consulting Ltd

Notes to the Financial Statements for the Year Ended 30 June 2018

1 General information

The company is a private company limited by share capital, incorporated in England and Wales.

The address of its registered office is:

St Matthew's House
Quays Office Park
Conference Avenue
Portishead
Bristol
BS20 7LZ

The principal place of business is:

40 Aldercombe Road
Bristol
BS9 2QL

These financial statements were authorised for issue by the director on 29 March 2019.

2 Accounting policies

Summary of significant accounting policies and key accounting estimates

The principal accounting policies applied in the preparation of these financial statements are set out below. These policies have been consistently applied to all the years presented, unless otherwise stated.

Statement of compliance

These financial statements have been prepared in accordance with Financial Reporting Standard 102 Section 1A - 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' and the Companies Act 2006.

Basis of preparation

These financial statements have been prepared using the historical cost convention except that as disclosed in the accounting policies certain items are shown at fair value.

Revenue recognition

Turnover comprises the fair value of the consideration received or receivable for the sale of goods and provision of services in the ordinary course of the company's activities. Turnover is shown net of sales/value added tax, returns, rebates and discounts.

The company recognises revenue when:

The amount of revenue can be reliably measured;

it is probable that future economic benefits will flow to the entity;

and specific criteria have been met for each of the company's activities.

Tax

The tax expense for the period comprises current and deferred tax. Tax is recognised in profit or loss, except that a change attributable to an item of income or expense recognised as other comprehensive income is also recognised directly in other comprehensive income.

The current income tax charge is calculated on the basis of tax rates and laws that have been enacted or substantively enacted by the reporting date in the countries where the company operates and generates taxable income.

Clinpharm Consulting Ltd

Notes to the Financial Statements for the Year Ended 30 June 2018

Deferred tax is recognised in respect of all timing differences between taxable profits and profits reported in the financial statements.

Unrelieved tax losses and other deferred tax assets are recognised when it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

Deferred tax is measured using the tax rates and laws that have been enacted or substantively enacted by the reporting date and that are expected to apply to the reversal of the timing difference.

Tangible assets

Tangible assets are stated in the statement of financial position at cost, less any subsequent accumulated depreciation and subsequent accumulated impairment losses.

The cost of tangible assets includes directly attributable incremental costs incurred in their acquisition and installation.

Depreciation

Depreciation is charged so as to write off the cost of assets, other than land and properties under construction over their estimated useful lives, as follows:

Asset class	Depreciation method and rate
Office equipment	15% reducing balance

Cash and cash equivalents

Cash and cash equivalents comprise cash on hand and call deposits, and other short-term highly liquid investments that are readily convertible to a known amount of cash and are subject to an insignificant risk of change in value.

Trade debtors

Trade debtors are amounts due from customers for merchandise sold or services performed in the ordinary course of business.

Trade debtors are recognised initially at the transaction price. They are subsequently measured at amortised cost using the effective interest method, less provision for impairment. A provision for the impairment of trade debtors is established when there is objective evidence that the company will not be able to collect all amounts due according to the original terms of the receivables.

Trade creditors

Trade creditors are obligations to pay for goods or services that have been acquired in the ordinary course of business from suppliers. Accounts payable are classified as current liabilities if the company does not have an unconditional right, at the end of the reporting period, to defer settlement of the creditor for at least twelve months after the reporting date. If there is an unconditional right to defer settlement for at least twelve months after the reporting date, they are presented as non-current liabilities.

Trade creditors are recognised initially at the transaction price and subsequently measured at amortised cost using the effective interest method.

Share capital

Ordinary shares are classified as equity. Equity instruments are measured at the fair value of the cash or other resources received or receivable, net of the direct costs of issuing the equity instruments. If payment is deferred and the time value of money is material, the initial measurement is on a present value basis.

Clinpharm Consulting Ltd

Notes to the Financial Statements for the Year Ended 30 June 2018

Dividends

Dividend distribution to the company's shareholders is recognised as a liability in the financial statements in the reporting period in which the dividends are declared.

3 Staff numbers

The average number of persons employed by the company (including the director) during the year, was 1 (2017 - 1).

Clinpharm Consulting Ltd

Notes to the Financial Statements for the Year Ended 30 June 2018

4 Tangible assets

	Office equipment £	Total £
Cost or valuation		
At 1 July 2017	974	974
Additions	658	658
At 30 June 2018	1,632	1,632
Depreciation		
At 1 July 2017	328	328
Charge for the year	196	196
At 30 June 2018	524	524
Carrying amount		
At 30 June 2018	1,108	1,108
At 30 June 2017	646	646

5 Debtors

	2018 £	2017 £
Trade debtors	-	24,840
Other debtors	-	718
	-	25,558

6 Creditors

Creditors: amounts falling due within one year

	2018 £	2017 £
Due within one year		
Taxation and social security	4,341	6,054
Accruals and deferred income	4,008	3,399
Other creditors	19,219	11,701
	27,568	21,154

Clinpharm Consulting Ltd

Notes to the Financial Statements for the Year Ended 30 June 2018

7 Share capital

Alotted, called up and fully paid shares

	2018		2017	
	No.	£	No.	£
Ordinary shares of £1 each	100	100	100	100

Page 8

This document was delivered using electronic communications and authenticated in accordance with the registrar's rules relating to electronic form, authentication and manner of delivery under section 1072 of the Companies Act 2006.